643bb711-7302-4ba7-bd39-cb0e4d9c2377
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.290
- MYC_TARGETS_V2+0.230
- MITOTIC_SPINDLE+0.190
- MYOGENESIS+0.120
- P53_PATHWAY+0.110
- ANGIOGENESIS+0.090
- KRAS_SIGNALING_DN+0.090
- PI3K_AKT_MTOR_SIGNALING+0.090
- APICAL_SURFACE+0.080
- PEROXISOME+0.060
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.460
- TNFA_SIGNALING_VIA_NFKB-0.460
- ALLOGRAFT_REJECTION-0.410
- INTERFERON_ALPHA_RESPONSE-0.410
- IL6_JAK_STAT3_SIGNALING-0.400
- CHOLESTEROL_HOMEOSTASIS-0.370
- INFLAMMATORY_RESPONSE-0.330
- COMPLEMENT-0.300
- IL2_STAT5_SIGNALING-0.290
- PROTEIN_SECRETION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4e24bc58-d246-4c96-952a-a18f95d142b2 | — | — | 0.804 |
| 2 | SRR1470175 | GTEX | — | 0.801 |
| 3 | ea89121f-2c74-433d-8047-898dc963bf35 | — | — | 0.795 |
| 4 | AUR-AD9E-TTM2-A-1-1-R-A542-39 | — | B | 0.787 |
| 5 | SRR614310 | GTEX | — | 0.786 |
| 6 | MNG857 | — | — | 0.782 |
| 7 | SRR602704 | GTEX | — | 0.776 |
| 8 | SRR17866827 | — | — | 0.775 |
| 9 | SRR1353176 | GTEX | — | 0.773 |
| 10 | SRR8613748 | — | D | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.010 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |